Gillessen, Silke ORCID: 0000-0001-5746-6555, Sauve, Nicolas, Collette, Laurence ORCID: 0000-0003-2518-7281, Daugaard, Gedske ORCID: 0000-0002-9618-9180, de Wit, Ronald, Albany, Costantine, Tryakin, Alexey ORCID: 0000-0003-2245-214X, Fizazi, Karim, Stahl, Olof, Gietema, Jourik A., De Giorgi, Ugo, Cafferty, Fay H., Hansen, Aaron R., Tandstad, Torgrim, Huddart, Robert A., Necchi, Andrea, Sweeney, Christopher J., Garcia-Del-Muro, Xavier, Heng, Daniel Y. C., Lorch, Anja, Chovanec, Michal, Winquist, Eric, Grimison, Peter, Feldman, Darren R., Terbuch, Angelika ORCID: 0000-0003-2918-1370, Hentrich, Marcus, Bokemeyer, Carsten, Negaard, Helene, Fankhauser, Christian, Shamash, Jonathan, Vaughn, David J., Sternberg, Cora N., Heidenreich, Axel and Beyer, Jorg (2021). Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. J. Clin. Oncol., 39 (14). S. 1563 - 1578. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755

Full text not available from this repository.

Abstract

PURPOSE The classification of the International Germ Cell Cancer Collaborative Group (IGCCCG) plays a pivotal role in the management of metastatic germ cell tumors but relies on data of patients treated between 1975 and 1990. MATERIALS AND METHODS Data on 9,728 men with metastatic nonseminomatous germ cell tumors treated with cisplatin- and etoposide-based first-line chemotherapy between 1990 and 2013 were collected from 30 institutions or collaborative groups in Europe, North America, and Australia. Clinical trial and registry data were included. Primary end points were progression-free survival (PFS) and overall survival (OS). The survival estimates were updated for the current era. Additionally, a novel prognostic model for PFS was developed in 3,543 patients with complete information on potentially relevant variables. The results were validated in an independent data set. RESULTS Compared with the original IGCCCG publication, 5-year PFS remained similar in patients with good prognosis with 89% (87%-91%) versus 90% (95% CI, 89 to 91), but the 5-year OS increased from 92% (90%-94%) to 96% (95%-96%). In patients with intermediate prognosis, PFS remained similar with 75% (71%-79%) versus 78% (76%-80%) and the OS increased from 80% (76%-84%) to 89% (88%-91%). In patients with poor prognosis, the PFS increased from 41% (95% CI, 35 to 47) to 54% (95% CI, 52 to 56) and the OS from 48% (95% CI, 42 to 54) to 67% (95% CI, 65 to 69). A more granular prognostic model was developed and independently validated. This model identified a new cutoff of lactate dehydrogenase at a 2.5 upper limit of normal and increasing age and presence of lung metastases as additional adverse prognostic factors. An online calculator is provided (https://www.eortc.org/IGCCCG-Update). CONCLUSION The IGCCCG Update model improves individual prognostication in metastatic nonseminomatous germ cell tumors. Increasing age and lung metastases add granularity to the original IGCCCG classification as adverse prognostic factors. (C) 2021 by American Society of Clinical Oncology.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Gillessen, SilkeUNSPECIFIEDorcid.org/0000-0001-5746-6555UNSPECIFIED
Sauve, NicolasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Collette, LaurenceUNSPECIFIEDorcid.org/0000-0003-2518-7281UNSPECIFIED
Daugaard, GedskeUNSPECIFIEDorcid.org/0000-0002-9618-9180UNSPECIFIED
de Wit, RonaldUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Albany, CostantineUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tryakin, AlexeyUNSPECIFIEDorcid.org/0000-0003-2245-214XUNSPECIFIED
Fizazi, KarimUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stahl, OlofUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gietema, Jourik A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
De Giorgi, UgoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Cafferty, Fay H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hansen, Aaron R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tandstad, TorgrimUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Huddart, Robert A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Necchi, AndreaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sweeney, Christopher J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Garcia-Del-Muro, XavierUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Heng, Daniel Y. C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lorch, AnjaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Chovanec, MichalUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Winquist, EricUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Grimison, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Feldman, Darren R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Terbuch, AngelikaUNSPECIFIEDorcid.org/0000-0003-2918-1370UNSPECIFIED
Hentrich, MarcusUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bokemeyer, CarstenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Negaard, HeleneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fankhauser, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Shamash, JonathanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Vaughn, David J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sternberg, Cora N.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Heidenreich, AxelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Beyer, JorgUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-608118
DOI: 10.1200/JCO.20.03296
Journal or Publication Title: J. Clin. Oncol.
Volume: 39
Number: 14
Page Range: S. 1563 - 1578
Date: 2021
Publisher: LIPPINCOTT WILLIAMS & WILKINS
Place of Publication: PHILADELPHIA
ISSN: 1527-7755
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
TESTICULAR CANCER; PROGNOSTIC-FACTORS; MARKER DECLINE; SURVIVAL; CISPLATIN; CLASSIFICATION; BLEOMYCIN; ETOPOSIDE; TRIAL; BEPMultiple languages
OncologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/60811

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item